HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation
Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Analyst Price Forecast Suggests 130.28% Upside